Knowstox

Fundamentals snapshot

West Pharmaceutical Services, Inc.

WST · NYQ · Healthcare · Medical Instruments & Supplies

Current price

$412.62

52-week range

$223.83 - $438.27

Market cap

$28.74B

One-glance verdict

Overvalued

$173.13 our estimate vs market $412.62

Wall Street consensus: $445.33 (157.2% higher than our fair-value estimate)

Balance sheet

Healthy

1,272.20x Strong cushion

Net cash $159.10M. Interest coverage shows how many times profit covers the interest bill.

What this company does

West Pharmaceutical Services, Inc.

West Pharmaceutical Services makes special packaging and delivery devices for medicines, like stoppers and seals for vials, and components for syringes, which are crucial for safely getting drugs to patients. Their money primarily comes from selling these high-quality components and services to drug companies worldwide. This is important because their products ensure the medicines inside are kept safe and effective, which directly impacts patient health and the success of the drugs developed by their customers.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q4 $85.20M FY2025 Q1 $58.10M FY2025 Q2 $101.90M FY2025 Q3 $133.90M FY2025 Q4 $175.00M FY2026 Q1 $47.20M FY2026 Q2 $80.80M FY2026 Q3 $150.40M
Revenue $874.50M
Net income $214.00M
Diluted EPS 3.02
Operating cash flow $189.50M
Free cash flow $150.40M
Revenue $872.30M
Net income $154.00M
Diluted EPS 2.15
Operating cash flow $124.00M
Free cash flow $80.80M
Revenue $844.90M
Net income $138.80M
Diluted EPS 1.92
Operating cash flow $89.90M
Free cash flow $47.20M
Revenue $805.00M
Net income $132.10M
Diluted EPS 1.82
Operating cash flow $251.10M
Free cash flow $175.00M
Revenue $804.60M
Net income $140.00M
Diluted EPS 1.92
Operating cash flow $197.20M
Free cash flow $133.90M
Revenue $766.50M
Net income $131.80M
Diluted EPS 1.82
Operating cash flow $177.10M
Free cash flow $101.90M
Revenue $698.00M
Net income $89.80M
Diluted EPS 1.23
Operating cash flow $129.40M
Free cash flow $58.10M
Revenue $748.80M
Net income $130.10M
Diluted EPS 1.78
Operating cash flow $190.10M
Free cash flow $85.20M

Is it cheap or expensive?

Fair value $173.13 vs current price $412.62

Wall Street consensus is the average analyst price target: $445.33 (157.2% higher than our fair-value estimate).

Our most-likely fair value is $173.13 a share — about 58.0% below today's price of $412.62, so the stock currently looks expensive (overvalued).

overvalued

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Base

Growth 10.0% · Discount 8.7% · Terminal 2.5%

$173.13

Bear

Growth 5.0% · Discount 8.7% · Terminal 2.5%

$131.16

Bull

Growth 15.0% · Discount 8.7% · Terminal 2.5%

$227.57

Is it drowning in debt?

Healthy

Net cash $159.1M - more cash than debt. Interest coverage 1272.2x.

Net debt $-159.10M
Interest coverage 1,272.20x

West Pharmaceutical Services, Inc.'s profit covers its interest bill about 1272.2 times over. which is stronger than every peer shown here and 1 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.

Healthy
Worse cushion Baseline Better cushion
WST BASELINE West Pharmaceutical Services, Inc.

Total debt $305.00M Interest coverage 1,272.20x This is the baseline the peer rows are being compared against.

Total debt $16.81B Interest coverage 4.87x -100% vs WST Carries about 261.2x less debt cushion than WST.

Total debt $8.81B Interest coverage 0.61x -100% vs WST Carries about 2084.4x less debt cushion than WST.

Total debt $1.38B Interest coverage 9.69x -99% vs WST Carries about 131.3x less debt cushion than WST.

Total debt $9.17B Interest coverage 6.78x -99% vs WST Carries about 187.6x less debt cushion than WST.

What you should know

The case for and against WST

3 Rewards 2 Risks

Rewards

  • Revenue grew 10.5% last year.
  • Returns 21.2% on equity, ahead of 80% of its peers.
  • Free cash flow was positive in 10/10 years.

Risks

  • Stock trades 28.4% above its 5-year average P/E.
  • Operating margin compressed from 26.4% to 25.1% over 3 years.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
52.83x
Forward P/E
41.33x
P/B
9.71x
P/S
8.46x
EV/EBITDA
29.73x
PEG ratio
3.21x

Profitability

How much profit each dollar creates

Gross margin
37.6%
Operating margin
25.1%
Net margin
18.8%
ROE
21.2%
ROA
11.9%

Health

Liquidity and balance-sheet strength

Debt / equity
0.10x
Current ratio
2.82x
Quick ratio
1.88x
Total debt
$305.00M
Total cash
$464.10M

Growth

How the business has been compounding

Revenue TTM
$3.40B
Revenue 5Y CAGR
2.1%
EPS TTM
7.81
EPS 5Y CAGR
-4.2%

Cash flow

How much cash the business throws off

Operating CF TTM
$654.50M
Free CF TTM
$468.90M
FCF margin
13.8%

Dividend

Shareholder payout

Yield
0.2%
Payout ratio
9.9%
Last ex-div date
2026-11-10